Talphera (TLPH) Common Equity (2010 - 2026)
Talphera (TLPH) posted Common Equity of $14.4 million for Q2 2026, down 22.04% on a QoQ basis from $18.5 million in Q1 2026, and up 117.38% year-over-year from $6.6 million in Q2 2025.
Analysis
Talphera (TLPH) Common Equity (2010 - 2026) Analysis & Trends
Talphera has reported Common Equity for 17 years, with the latest figure at $14.4 million in Q2 2026.
- On a quarterly basis, Common Equity rose 117.38% year-over-year to $14.4 million in Q2 2026; TTM through Jun 2026 was $14.4 million, a 117.38% increase from a year earlier, with the FY2025 full-year figure at $17.0 million, up 112.91% from the prior year.
- Common Equity was $14.4 million for Q2 2026 at Talphera, down from $18.5 million in the prior quarter.
- The five-year high for Common Equity was $33.1 million in Q2 2022, with the low at -$38.3 million in Q1 2022.
- Average Common Equity over 5 years is $12.7 million, with a median of $14.3 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: Common Equity plunged 68.56% in 2023, then soared 230.02% in 2026.
- Over 5 years, Common Equity stood at $21.8 million in 2022, then sank by 35.34% to $14.1 million in 2023, then plunged by 43.28% to $8.0 million in 2024, then soared by 112.91% to $17.0 million in 2025, then declined by 15.43% to $14.4 million in 2026.
- The last three Common Equity figures came in at $14.4 million (Q2 2026), $18.5 million (Q1 2026), and $17.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 14.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.41 Mn |
| Mar 31, 2026 | 18.48 Mn |
| Dec 31, 2025 | 17.04 Mn |
| Sep 30, 2025 | 19.18 Mn |
| Jun 30, 2025 | 6.63 Mn |
| Mar 31, 2025 | 5.60 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 12.73 Mn |
| Mar 31, 2024 | 16.33 Mn |
| Dec 31, 2023 | 14.11 Mn |
| Sep 30, 2023 | 18.31 Mn |
| Jun 30, 2023 | 10.42 Mn |
| Mar 31, 2023 | 14.24 Mn |
| Dec 31, 2022 | 21.81 Mn |
| Sep 30, 2022 | 27.23 Mn |
| Jun 30, 2022 | 33.14 Mn |
| Mar 31, 2022 | -38.27 Mn |
| Dec 31, 2021 | -35.89 Mn |
| Sep 30, 2021 | -43.02 Mn |